Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Velcade in myelodysplastic syndromes
2004-002935-23Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Mar 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in myelodysplastic syndrome (MDS), sponsored by GIMEMA. Started Mar 2007; status: terminated.
02
Drugs
bortezomib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2004-002935-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002935-23.